Condition: NSCLC · Brain Metastases · ROS1 Gene Rearrangement · Sponsor: MedSIR
REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.
This description comes directly from the study's public registry record.
MEDSIR · +34 93 2214135 · contact.trials@medsir.org
Always discuss trial participation with your own doctor first.
| Medizinische Universität Graz | Graz, Austria | Recruiting |
| Medical University of Vienna | Vienna, Austria | Recruiting |
| Ludwig-Maximilians-University Munich | München, Germany | Recruiting |
| Hospital de Vinalopó | Elche, Alicante, Spain | Recruiting |
| Hospital Universitari Sant Joan de Reus | Reus, Tarragona, Spain | Recruiting |
| Hospital General Universitario Dr. Balmis | Alicante, Spain | Recruiting |
| Hospital de Cruces | Barakaldo, Spain | Recruiting |
| UOMI Cancer Center | Barcelona, Spain | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Recruiting |
| Institut Català d' Oncologia Girona (ICO) | Girona, Spain | Recruiting |
| Hospital Universitario de León | León, Spain | Recruiting |
| Hospital Lucus Agusti | Lugo, Spain | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06315010